July 21, 2022
Japan’s all-important reimbursement policy panel on July 20 approved the results of cost-effectiveness assessments (CEAs) for Novo Nordisk Pharma’s oral GLP-1 agent Rybelsus (semaglutide), putting it in line for a downward price adjustment. Rybelsus, the first oral GLP-1 agent for...read more